02696.HK
Shanghai Henlius Biotech, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 70.10
+1.52%Aug 26, 2026, 13:54 UTC
Alligator Bioscience announced it is abandoning independent development of its lead cancer drug mitazalimab, shifting to a leaner model focused on its royalty interest in HLX22, and reducing staff and operating costs.
Source:Aug 26, 2026, 10:52 UTC
GIC Private Limited increased its stake in Shanghai Henlius Biotech (02696.HK) to 5.03% by buying 232,200 H-shares at an average price of HK$68.6666 per share on August 21, 2026.
Source:Aug 21, 2026, 12:16 UTC
Shanghai Henlius Biotech disclosed its interim results for the first half of 2026, reporting revenue of 3.5882 billion yuan, up 27.3% year-on-year, and net profit of 430.4 million yuan, up 10.3%.
Aug 21, 2026, 12:16 UTC
Shanghai Henlius Biotech was selected for inclusion in the Hang Seng Composite Index, effective September 7, 2026, following the latest quarterly review by Hang Seng Indexes Company.
Source:Aug 16, 2026, 23:48 UTC
Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.
Jul 31, 2026, 08:34 UTC
Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.
Jul 30, 2026, 09:27 UTC
Shanghai Henlius Biotech (02696) announced that the first patient has been dosed in a Phase 1 clinical study of its self-developed HLX3902 injection for metastatic castration-resistant prostate cancer and other advanced solid tumors in China (excluding Hong Kong, Macau, and Taiwan).
Source:Jul 16, 2026, 08:37 UTC
Shanghai Henlius Biotech (02696) announced that its self-developed nivolumab biosimilar HLX18 has completed first patient dosing in a Phase 1 clinical trial in China for multiple resected solid tumors.
Source:Jul 10, 2026, 08:35 UTC
Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.
Jul 8, 2026, 09:26 UTC
Shanghai Henlius Biotech announced that the first patient has been dosed in the Phase 1 clinical trial of its self-developed biosimilar HLX05-N (cetuximab injection) for metastatic colorectal cancer in China.
Source:Jun 25, 2026, 20:57 UTC
Shanghai Henlius Biotech announced that the European Commission approved serplulimab for first-line treatment of squamous non-small cell lung cancer, its fourth EU indication.
Source:Jun 23, 2026, 09:30 UTC
Organon Canada and Shanghai Henlius Biotech launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA, in Canada.
Source: